Publication date: Dec 17, 2025
The frequency of new and re-emerging viral infections is rising, driven by shifts in environmental conditions and altered interactions between hosts, vectors, and pathogens. New treatments may be developed through a better understanding of the molecular processes underlying viral replication. The low-density lipoprotein receptor (LDLR) serves as a critical entry portal for a diverse range of infectious agents, facilitating the initiation and perpetuation of their infection cycles. Furthermore, numerous viruses, such as the dengue virus and the hepatitis C virus (HCV), depend on host cholesterol (CHO) for replication and spread. Consequently, targeting the LDLR with pharmacological agents presents a promising therapeutic strategy for a broad spectrum of viral infections, including those caused by human immunodeficiency virus (HIV), HCV, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, human metapneumovirus (HMPV) is a leading cause of respiratory infections in young children, underscoring the need for effective treatments. This research investigates the role of the LDLR in HMPV and other emerging viruses. A key finding is that HMPV infection depends on LDLR-mediated pathways, as evidenced by the rapid recovery observed after exogenous CHO administration. Therefore, understanding the mechanism of LDLR in viral entry and replication is crucial and presents a promising avenue for developing novel antiviral therapies.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | viral infections |
| drug | DRUGBANK | Tropicamide |
| pathway | KEGG | Viral replication |
| disease | MESH | infection |
| disease | MESH | dengue |
| disease | MESH | hepatitis C |
| pathway | KEGG | Hepatitis C |
| drug | DRUGBANK | Cholesterol |
| disease | MESH | severe acute respiratory syndrome |
| disease | MESH | respiratory infections |
| disease | MESH | Communicable Diseases Emerging |
| disease | MESH | Paramyxoviridae Infections |